SCHEMBL30765778

SCHEMBL30765778

O=C(O)Cn1c(N2CC(F)C2)ncc(NCc2ccc3oc4ccccc4c3c2)c1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
HTT P42858 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HCRTR1 O43613 12/20 0.35
HCRTR2 O43614 12/20 0.35
CYP3A4 P08684 4/20 0.35
HDAC6 Q9UBN7 1/20 0.34
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765939 0.92 LMNA (0.35) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765836 0.88 KDM4E (0.36) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765535 0.82 F2 (0.34) ALDH1A1MAPTKMT2AHDAC6
SCHEMBL30765838 0.82 CASP1 (0.41) LMNAHPGDKDM4EHTTHSD17B10
SCHEMBL30765580 0.81 ELANE (0.39) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765947 0.80 LMNA (0.40) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765465 0.77 LMNA (0.39) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765805 0.76 LMNA (0.39) LMNAHPGDKDM4EMEN1ALDH1A1
SCHEMBL30765916 0.75 CMA1 (0.41) LMNA
SCHEMBL31558430 0.75 HDAC6 (0.47) LMNAHPGDKDM4EMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed